**Guideline Page and Request** | **Panel Discussion** | **References** | **Vote**  
--- | --- | --- | ---  
**ENDO-B**  
Internal request: Add liposomal doxorubicin as an agent for recurrent, metastatic or high-risk disease in endometrial carcinoma  
Based upon the noted references, the panel agreed to add liposomal doxorubicin as an agent for recurrent, metastatic or high-risk disease in endometrial carcinoma.  
YES | NO | ABSTAIN  
16 | 2 | 2